|
80
|
296
|
2x1nA |
Truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design |
|
99
|
258
|
2wmbB |
Structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment site of cyclin a |
|
96
|
258
|
2x1nB |
Truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design |
|
89
|
258
|
2wpaB |
Optimisation of 6,6-dimethyl pyrrolo 3,4-c pyrazoles: identification of pha-793887, a potent cdk inhibitor suitable for intravenous dosing |
|
84
|
302
|
2wxvA |
Structure of cdk2-cyclin a with a pyrazolo(4,3-h) quinazoline-3- carboxamide inhibitor |
|
93
|
258
|
2wipB |
Structure of cdk2-cyclin a complexed with 8-anilino-1-methyl-4,5-dihydro- 1h-pyrazolo[4,3-h] quinazoline-3-carboxylic acid |
|
86
|
302
|
2wihA |
Structure of cdk2-cyclin a with pha-848125 |
|
96
|
257
|
2wihB |
Structure of cdk2-cyclin a with pha-848125 |
|
87
|
302
|
2wipA |
Structure of cdk2-cyclin a complexed with 8-anilino-1-methyl-4,5-dihydro- 1h-pyrazolo[4,3-h] quinazoline-3-carboxylic acid |
|
89
|
258
|
2whbB |
Truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design |
|
75
|
296
|
2whbA |
Truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design |
|
92
|
257
|
2wfyB |
Truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design |
|
91
|
297
|
2wmbA |
Structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment site of cyclin a |
|
0
|
5
|
2wmbI |
Structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment site of cyclin a |
|
100
|
258
|
2wmaB |
Structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment site of cyclin a |
|
95
|
257
|
2wxvB |
Structure of cdk2-cyclin a with a pyrazolo(4,3-h) quinazoline-3- carboxamide inhibitor |
|
85
|
302
|
2wpaA |
Optimisation of 6,6-dimethyl pyrrolo 3,4-c pyrazoles: identification of pha-793887, a potent cdk inhibitor suitable for intravenous dosing |
|
76
|
297
|
2wmaA |
Structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment site of cyclin a |
|
80
|
295
|
2wfyA |
Truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design |
|
77
|
298
|
2w1hA |
Fragment-based discovery of the pyrazol-4-yl urea (at9283), a multi- targeted kinase inhibitor with potent aurora kinase activity |
|
86
|
296
|
2wevA |
Truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design |
|
95
|
258
|
2wevB |
Truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design |
|
79
|
298
|
2vthA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design |
|
78
|
298
|
2vtiA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. |
|
77
|
298
|
2vtjA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design |
|
78
|
298
|
2vtaA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. |
|
84
|
298
|
2vtlA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design |
|
82
|
298
|
2vtmA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. |
|
80
|
298
|
2vtqA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. |
|
81
|
298
|
2vtpA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. |
|
75
|
298
|
2vtsA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. |
|
74
|
298
|
2w17A |
Cdk2 in complex with the imidazole pyrimidine amide, compound (s)-8b |
|
76
|
298
|
2w06A |
Structure of cdk2 in complex with an imidazolyl pyrimidine, compound 5c |
|
76
|
298
|
2w05A |
Structure of cdk2 in complex with an imidazolyl pyrimidine, compound 5b |
|
78
|
298
|
2vv9A |
Cdk2 in complex with an imidazole piperazine |
|
75
|
298
|
2vttA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. |
|
78
|
298
|
2vtoA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. |
|
82
|
298
|
2vtrA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design |
|
79
|
298
|
2vtnA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. |
|
79
|
298
|
2vu3A |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. |
|
88
|
296
|
2uzdA |
Crystal structure of human cdk2 complexed with a thiazolidinone inhibitor |
|
97
|
257
|
2uzlB |
Crystal structure of human cdk2 complexed with a thiazolidinone inhibitor |
|
76
|
296
|
2uzoA |
Crystal structure of human cdk2 complexed with a thiazolidinone inhibitor |
|
75
|
298
|
2uznA |
Crystal structure of human cdk2 complexed with a thiazolidinone inhibitor |
|
87
|
296
|
2uzeA |
Crystal structure of human cdk2 complexed with a thiazolidinone inhibitor |
|
95
|
258
|
2uzdB |
Crystal structure of human cdk2 complexed with a thiazolidinone inhibitor |
|
94
|
258
|
2v22B |
Replace: a strategy for iterative design of cyclin binding groove inhibitors |
|
82
|
296
|
2v22A |
Replace: a strategy for iterative design of cyclin binding groove inhibitors |
|
78
|
298
|
2v0dA |
Crystal structure of human cdk2 complexed with a thiazolidinone inhibitor |
|
98
|
258
|
2uzeB |
Crystal structure of human cdk2 complexed with a thiazolidinone inhibitor |
